FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Ballinger Kevin J. 		2. Issuer Name and Ticker or Trading Symbol

BOSTON SCIENTIFIC CORP [ BSX ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
EVP & Pres, Interven Cardio
(Last)          (First)          (Middle)

300 BOSTON SCIENTIFIC WAY 		3. Date of Earliest Transaction (MM/DD/YYYY)

2/28/2017
(Street)

MARLBOROUGH, MA 01752-1234
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

3/1/2017 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Deferred Stock Units     (1) 3/3/2017     A      16513.0000         (2) 3/3/2022   (2) Common Stock   16513.0000   $0.0000   16513.0000   D    
Performance Share Units     (3) 3/3/2017     A      16513.0000   (4)      12/31/2018   (4) 12/31/2018   (4) Common Stock   16513.0000   $0.0000   16513.0000   (4) D    
Stock Option (Right to Buy)   $24.9800   3/3/2017     A      52816.0000         (5) 3/3/2027   Common Stock   52816.0000   $0.0000   52816.0000   D    

Explanation of Responses:
( 1)  Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
( 2)  Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant.
( 3)  Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
( 4)  On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On March 3, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2018.
( 5)  Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant.

Remarks:
On March 1, 2017, the reporting person mistakenly filed a Form 4 reporting in Table II the grant of deferred stock units, performance share units and stock options (right to buy), which did not occur. This Form 4 reports the grants of deferred stock units, performance share units and stock options (right to buy) that occurred on March 3, 2017.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Ballinger Kevin J.
300 BOSTON SCIENTIFIC WAY
MARLBOROUGH, MA 01752-1234

EVP & Pres, Interven Cardio

Signatures
/s/ Vance R. Brown, Attorney-in-fact 3/6/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Boston Scientific Charts.
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Boston Scientific Charts.